Werewolf Therapeutics Inc

NASDAQ HOWL

Data sourced from

and

Download Data

Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: 89.24%

Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) is 89.24% for the quarter ending March 31, 2024. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2023 was -0.45, a 0.00% change year over year.
Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2022 was -0.00, a 0.00% change year over year.
Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2021 was -0.00, a 0.00% change year over year.
Werewolf Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2020 was -0.00.

NASDAQ: HOWL

Werewolf Therapeutics Inc

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key trends